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Abstract 
Tumor necrosis factor (TNF)-α is a proinflammatory cytokine with a role in immunity to 
pathogens, as well as in the pathogenesis of several autoimmune/inflammatory diseases. 
Biological drugs targeting this cytokine and inhibiting its effects are designed. Until today, five 
TNF-α inhibitors are approved: infliximab, adalimumab, golimumab (monoclonal antibodies), 
certolizumab pegol (pegylated antigen-binding fragment of immunoglobulin), and etanercept 
[TNF receptor type 2-fragment crystallizable (Fc) of immunoglobulin fusion protein]. Their 
approved biosimilars are on the market, too. They are mainly used for the treatment of rheumatoid 
arthritis, inflammatory bowel disease, and psoriasis. Although TNF-α inhibitors are present in 
clinical practice for more than two decades and are established as an efficacious therapeutics, 
researchers are still occupied by revealing the complex mechanisms of their action. Namely, in 
addition to binding and neutralisation of soluble TNF-α, these drugs also bind/block 
transmembrane form of TNF-α (tmTNF-α), trigger diverse intracellular signals in tmTNF-α 
positive cells (a process named “reverse signalling”) or, if they have an Fc fragment, mediate 
killing of tmTNF-α-expressing cells by other immune cells or the complement system. Also, 
TNF-α inhibitors that contain Fc portion of the IgG antibody may affect Fc receptor-expressing 
cells and have an effector function quite independent of their TNF-α neutralisation capacity.  
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Tumor necrosis factor (TNF)-α inhibitors are in use for more than two decades in 
the treatment of autoimmune/inflammatory diseases where overproduction of TNF-α, a 
potent proinflammatory cytokine, has an important role in pathogenesis (1). Currently, 
five TNF-α inhibitors (infliximab, adalimumab, etanercept, certolizumab pegol and 
golimumab) are approved by the U.S. Food and Drug Administration and European 
Medicines Agency (Table I). The first three drugs were initially developed for the therapy 
of rheumatoid arthritis (RA), but current indications also include inflammatory bowel 
disease (IBD), psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic 
arthritis and hidradenitis suppurativa (1, 2) (Table II). 
Anti-TNF-α agents are primarily developed to target soluble (s)TNF-α and inhibit 
its action. However, although these drugs were equally successful in the treatment of RA, 
their efficacy differs when they are used in the therapy of IBD (3, 4). These findings 
pointed out that TNF-α inhibitors act in a way more complex than a simple neutralisation 
of sTNF-α. Thus their effects may also include blocking transmembrane (tm)TNF-α and 
lymphotoxin (LT), signalling through tmTNF-α, and/or effects by fragment crystallizable 
(Fc)γ receptor (FcγR)-expressing cells (3, 4). 
 
Revealing and understanding the mechanisms of action for biologic agents targeting 
TNF-α, could significantly improve the efficacy of this class of drugs and contribute to 
the reduction of their side effects. 
TNF-α 
TNF-α was discovered in 1975 as a molecule whose production was induced by 
endotoxin and was able to provoke hemorrhagic necrosis of sarcomas transplanted into 
mice (5). It is known as the cytokine with the most pleiotropic effects of all mammalian 
cytokines, and its biologic effects are mediated through membrane receptors on different 
cell types (6). TNF-α is produced in a large amounts during infections with Gram-
negative and Gram-positive bacteria and is responsible for systemic complications in 
severe infections (6,7). Also, the development of some autoimmune/inflammatory 
diseases, such as RA, IBD, psoriasis, and others, as well as cancers and cardiovascular 
diseases is linked with uncontrolled production and/or function of this cytokine (2, 8). In 
addition to its role in immunity to pathogens and autoimmune/inflammatory diseases, 
TNF-α also has a homeostatic function which is mediated by molecular and cellular 
pathways distinct from pathogenic ones (2, 8). 
Production and structure of TNF-α 
The main TNF-α producers are activated mononuclear phagocytes, activated T-




osteoclasts, neutrophils, smooth, and cardiac muscle cells can produce this cytokine as 
well (7, 8). Production of this cytokine is induced upon activation of several receptors of 
innate immunity, either by microbial (e.g. lipopolysaccharide; LPS) or endogenous 
(cytokines, damaged cells) products (9). 
In the cells that produce TNF-α, it is firstly synthesized and expressed in a form of 
a transmembrane protein, also known as pro-TNF-α (3, 6, 7). Membrane-associated 
metalloproteinases called TNF-α converting enzyme, cleave the membrane form and 
release a sTNF-α that circulates through the body and can act, contrary to tmTNF-α, at 
sites that are distant from the site of synthesis (3, 6, 7). Both forms of the cytokine, 
membrane, and soluble, are homotrimers. Three 17 kDa-subunits polymerize and form a 
triangular pyramidal structure of sTNF-α, where each side of the pyramid is formed by 
one subunit. Receptor-binding sites are at the base of the pyramid, allowing simultaneous 
binding of the cytokine to three receptor molecules. The tmTNF-α also appears as a 
homotrimer consisting of uncleaved monomers, 26 kDa each (3, 7, 10). 
TNF receptors 
TNF-α exerts its effect by binding to TNF receptors type 1 (TNFR1) and type 2 
(TNFR2), and both forms of cytokine act through both types of TNFR. However, sTNF-
α has a significant preference for TNFR1, while tmTNF-α is a more potent ligand for 
TNFR2 (3, 6). 
These two receptors have different patterns of expression, a different affinity for 
ligands, and activate various signalling pathway upon ligand binding (1). Also, their 
expressions are differently regulated in health and disease (1). TNFR1 is constitutively 
expressed on almost all nucleated cells and has a role in initiating inflammatory reaction 
and mediating apoptosis (1). Expression of TNFR2 is inducible and is limited to specific 
cell types (endothelial cells, lymphocytes, cardiac myocytes, oligodendrocytes, 
microglia, and astrocytes) (11). It appears that it has an important role in homeostasis and 
tissue repair, and is activated mainly by tmTNF-α (1, 3, 12). 
Interestingly, tmTNF-α transmits signal not only as a ligand but also as a receptor 
through the cell to cell contact, acting as a bipolar molecule (3). When it acts as a ligand, 
tmTNF-α-bearing cells, in direct contact-dependent fashion, induce signals in target cells 
that express TNFR1 and/or TNFR2. Also, binding of TNFR to tmTNF-α results in 
signalling back in tmTNF-α-bearing cell, in the process known as “outside-to-inside 
signalling” or “reverse signalling” (6, 13). The biological significance of reverse 
signalling has not yet been elucidated completely (3).  
Roles of TNF-α in health and disease 
The main physiological role of TNF-α is in host defence to bacteria, viruses, and 




harmful (7). As previously mentioned, it acts proinflammatory, and many of the effects 
can be explained by its local action on vascular endothelium and consequently on 
interactions between leukocytes and endothelial cells at the site of infection (7). Namely, 
in response to this cytokine, endothelial cells express different combinations of adhesion 
molecules, which in combination with the secretion of various chemokines (14), recruit 
different populations of leukocytes to the site of infection, independently of antigen 
recognition (7). Additionally, TNF-α induces expression of cyclooxygenase-2 in 
endothelial cells and increases the production of vasodilatory prostaglandin I2, causing 
‘rubor’ and ‘calor’ due to increased local blood flow (15). Increased vascular 
permeability, mediated by TNF-α, contributes to the development of oedema by 
increasing trans-endothelial passage of fluid and macromolecules into the site of 
inflammation. Moreover, TNF-α-related expression of procoagulant proteins and down-
regulation of anticoagulant proteins may result in intravascular thrombosis (16). Also, 
TNF-α could enhance the antigen presenting function of dendritic cells and, as a result, 
activate T cells and stimulate adaptive immunity (14). In severe infections, TNF-α is 
produced in large quantities, enters the bloodstream, and can cause systemic effects 
(fever, synthesis of acute phase proteins, shock, intravascular thrombosis, hypoglycemia, 
cachexia) (17). 
In addition to its role in defence against pathogens, TNF-α has a number of 
homeostatic effects, including the proper formation of lymphoid organs and germinal 
centres, development of granulomas, resolution of inflammation, induction of tissue 
repair and inhibition of tumorigenesis (2, 12).  
Uncontrolled production or function of TNF-α has been associated, as previously 
mentioned, with the development of autoimmune/inflammatory diseases (2). In RA, a 
chronic autoimmune disease that affects synovial tissues, proinflammatory cytokines 
such as interleukin (IL)-1, IL-6, and TNF-α, are detected in the affected, inflamed joints 
(18). Numerous in vivo and in vitro studies have demonstrated that TNF-α has a dominant 
role in RA pathogenesis (19, 20, 21, 22). In RA patients, accumulation of inflammatory 
cells, synovial hyperplasia and angiogenesis are seen in affected joints (23). In another 
rheumatic disease, ankylosing spondylitis, TNF-α has been detected in early active 
lesions in sacroiliac joints, the main sites of inflammation (24), while an elevated level of 
this cytokine was measured in patients` serum (25). Crohn`s disease (CD) and ulcerative 
colitis (UC) are chronic inflammatory disorders that belong to the group of IBD and affect 
every part of the gastrointestinal tract and colonic mucosa, respectively (26). Increased 
expression of TNF-α in the lamina propria of the intestinal specimens from patients with 
CD and UC (27, 28), as well as the finding that mice who overexpressed TNF-α develop 
a CD-like IBD (29) speaks in favor of its importance in the pathogenesis of these diseases. 




infiltrate is found in hyperkeratotic lesions, and TNF-α, TNFR1, and TNFR2 are found 
to be overexpressed in dermal blood vessels of involved skin (30). 
TNF-α inhibitors 
As abovementioned, among the five approved TNF-α inhibitors, infliximab, 
adalimumab and golimumab are monoclonal antibodies (mAbs), certolizumab pegol is 
Fc-free, PEGylated mAb and etanercept is a fusion protein (Table I). 
Additionally, the patents of etanercept, infliximab and adalimumab expired, and 
thus several anti-TNF-α biosimilars are already on the market, while a number of them 
are pending for approval or are in the development process (Table I). 
 
Table I  TNF-α inhibitors and their biosimilars. 
 
The number in parentheses indicates the year of approval; FDA-Food and Drug Administration; 





TNF-α inhibitors are used to treat RA, CD, UC, psoriatic arthritis, polyarticular 
juvenile idiopathic arthritis, ankylosing spondylitis, hidradenitis suppurativa and uveitis 




pyoderma gangrenosum, TNFR-associated periodic fever syndrome, adult-onset Still 
disease, and systemic-onset juvenile idiopathic arthritis (1, 31). 
 
Table II  Approved indications of TNF-α inhibitors. 
 
Modified from Lis et al.(1)  
 
Etanercept (Enbrel®) is the first TNF-α inhibitor approved for the treatment of RA, 
and the first recombinant receptor: immunoglobulin (Ig) fusion protein approved for 
therapeutic use in humans. It contains two extracellular portions of the human TNFR2 
and Fc region of human Ig-G1. This Fc region has a hinge, heavy chain constant domains 
(CH) 2 and 3, but does not have a CH1 domain (3) (Table I, Figure 1). For its production, 
recombinant DNA technology utilizing Chinese hamster ovary (CHO) mammalian cell 
expression system was used (32). Etanercept, with its dimeric structure, has a greater 
affinity of binding and greater competitive inhibition of TNF-α compared with 
monomeric soluble receptors (32, 33). Also, possession of the IgG Fc region as a fusion 
element contributes to its longer half-life in serum, in comparison with monomeric 
soluble receptors (32). Etanercept is the only TNF-α inhibitor that competitively inhibits 
the binding of both TNF-α and LT-α to TNFR1 and TNFR2 (32). 
Infliximab (Remicade®) is a monoclonal, chimeric anti-TNF-α mAb with 
specificity for human TNF-α. It consists of murine variable regions of Ig heavy and k 
light chain (25% of the molecule) and a human IgG1 constant region (75% of the 




Adalimumab (Humira®) is the first fully human high-affinity mAb produced by 
„phage-display“ technology in CHO mammalian cell line. This antibody contains heavy- 
and light- chain variable regions and constant IgG1:k region of human origin. It is highly 
selective for s- and tm-TNF-α and does not bind to other cytokines (35) (Table I, Figure 
1). 
Golimumab (Simponi®) is also human IgG1:k mAb with high affinity and 
selectivity to TNF-α. Unlike adalimumab, it is produced by a cell line of murine 
hybridomas with recombinant DNA technology using transgenic mice (36). These mice 
are engineered to express human IgG transgenes and after immunization with human 
recombinant TNF-α they synthesize and secrete high-affinity human mAb specific for 
human TNF-α (36) (Table I, Figure 1).  
Certolizumab pegol (Cimzia®) consists of monovalent antigen-binding fragment 
(Fab’) of humanized (approximately 95% human) IgG1 that is specific for TNF-α and 
two polyethylene glycol (PEG) chains covalently linked to hinge portion of the molecule 
(Table I, Figure 1). Although it lacks the Fc region, pegylation prolongs its half-life and 





Figure 1. Structure of TNF-a inhibitors. Infliximab is a mouse/human chimeric monoclonal  
 anti-TNF-α IgG1 antibody. Adalimumab and golimumab are human monoclonal  
 anti-TNF-α IgG1 antibodies. Etanercept is a fusion protein consisting of two  
 extracellular domains of human TNFR2 and the Fc region of IgG1. Certolizumab  
 pegol is a pegylated Fab’ fragment of humanized monoclonal anti-TNF-α  
 antibody. CH-heavy chain constant domain, PEG- polyethylene glycol,                        




All the abovementioned biological agents have revolutionized RA treatment, 
whereas their efficacy in the treatment of CD and UC is not equal (3, 4). Namely, while 
full anti-TNF-α mAbs (infliximab, adalimumab, and golimumab) can induce clinical and 
endoscopic remission in patients with IBD, certolizumab pegol, which lacks the Fc 
fragment, was less effective than full mAbs, whereas no evidence exists that etanercept 
can induce clinical remission in IBD (3, 4). It is assumed that structural 
characteristics/differences between the drugs influence their mechanisms of action and 
are the cause of the variations in the efficacy in the treatment of IBD (9).  
Mechanisms of action  
Although TNF-α inhibitors are more than 20 years in use, the mechanisms of their 
action have not yet been fully clarified. Primary, they are developed to bind and directly 
neutralise sTNF-α activity, i.e. to antagonize/block its signalling (9). However, since 
etanercept, TNF-α inhibitor that targets sTNF-α, has been successful in RA, but not in 
IBD treatment (4, 9, 37), it has been supposed that mechanisms of action of these drugs 
are much more complex. Today, it is known that other mechanisms contributing to the 
biological activity of these drugs may include their effects through binding to tmTNF-α- 
and FcγR-expressing cells (38, 39, 40, 41, 42, 43, 44, 45).  
Neutralisation of TNF-α 
Even though all TNF-α inhibitors have the same target, there are differences in their 
characteristics of binding, and in the way they neutralise TNF-α (40). Generally, all anti-
TNF-α agents bind and neutralise sTNF-α, but their binding affinity is different (3, 4, 38, 
41). Also, it has been reported that the affinity of these agents for tmTNF-α is lower than 
for its soluble form (38, 41). This could be, at least partly, explained by the fact that the 
effects of these drugs on cells that express tmTNF-α also depend on the concentration of 
sTNF-α and therefore on the availability of the free TNF-α inhibitor (46). However, data 
regarding the binding affinity of different TNF-α inhibitors for tmTNF-α are 
contradictory. Some studies showed no difference in their affinity of binding (38), 
whereas others found that etanercept does either not bind or binds with low affinity (40, 
41, 43, 44). Found discrepancies can be explained by different cell types, methods, and 
techniques that were used for affinity assessment (4). Since it has been shown that 
TNFR2, which is a part of etanercept, dissociates swiftly from both sTNF-α and tmTNF-
α, etanercept TNF-α neutralisation capacity is probably short-lived (40). An unstable 
complex of etanercept/TNF-α contributes to the longer half-life of the drug, but TNF-α 
released from the complex is biologically active and can bind to its natural receptors (40). 
Thus, if there is no enough etanercept in tissue to prevent the binding of TNF-α to its 
natural receptors, incomplete inhibition of proinflammatory action of TNF-α can be 




Furthermore, different TNF-α inhibitors have been shown to differ in their ability 
to cross-link tmTNF-α. It has been shown that up to three infliximab molecules can bind 
to each tmTNF-α homotrimer, resulting in blocking all receptor-binding sites on this 
cytokine (40). Contrary to this, etanercept binds to tmTNF-α trimer in a one-to-one ratio, 
blocking two of the three receptor binding sites, so that one receptor binding site stays 
open/free (40). Thus, it is hypothesized that the flexibility of etanercept, compared with 
infliximab, is reduced, and thus cross-linking of multiple tmTNF-α molecules is 
prevented (47). All abovementioned data, together with the fact that infliximab forms 
more stable complexes with tmTNF-α, the neutralisation of which, rather than 
neutralisation of sTNF-α, is crucial in the therapy of IBD, could be a possible explanation 
why infliximab is effective in the therapy of IBD whereas etanercept did not show any 
clinical efficacy in patients with CD, and therefore received no approval for IBD 
treatment (4). 
Neutralisation of LTα 
Etanercept, contrary to infliximab and adalimumab, binds and neutralises LTα3, a 
cytokine that acts through TNFR1 and TNFR2 (3, 38, 40). Since LTα3 has a role in RA 
pathogenesis, its neutralisation by etanercept suppresses inflammation and has a 
favorable effect on this disease (3). The role of LTα3 in the pathogenesis of IBD has not 
been sufficiently studied. It is supposed that the other form of LT, LTα1β2, could have a 
role in the pathogenesis of IBD, but the effects of this cytokine are mediated by LTβ 
receptor, and it can not be neutralised by etanercept (3). 
Effects on cells that express tmTNF-α  
The binding of TNF-α inhibitors to tmTNF-α can induce effects on the tmTNF-α-
bearing cells that are, on the one side, the result of reverse signal transduction, and on the 
other side, may be Fc region-mediated (if the drug has an Fc region), such as cytotoxicity 
induced by complement and NK cell activation (4).  
Reverse signalling   
As abovementioned, tmTNF-α functions not only as a ligand but also as a receptor 
(3, 4). Thus, TNF-α inhibitors in addition to be considered as antagonists, in the case of 
binding to tmTNF-α can trigger reverse signalling, and might be also viewed as agonists 
(48). 
For the induction of signalling in tmTNF-α-expressing cells (reverse signalling), it 
is necessary that TNF-α inhibitor binds to tmTNF-α with high avidity and form a stable 
complex, or to cross-link multiple tmTNF-α molecules (9, 49, 50). As mentioned above, 
etanercept does not bind to all binding sites of tmTNF-α, and it forms less stable 
complexes compared to infliximab (40), which makes it less efficient in inducing reverse 




Acting as agonists, TNF-α inhibitors suppress the production of inflammatory 
mediators, induce apoptosis of activated immune cells and block activation and 
proliferation of immune cells (3, 4, 9). Namely, several in vitro studies have shown that 
TNF-α inhibitors (infliximab, adalimumab, and certolizumab pegol), through reverse 
signalling, suppress the expression of proinflammatory cytokines (TNF, IL-1β, and IL-6) 
in LPS-stimulated human monocytes of healthy individuals and/or patients with CD and 
RA (9, 50, 51, 52). Etanercept showed a weaker suppressive effect on the production of 
proinflammatory cytokines by reverse signal transduction (39, 50), which may explain its 
inefficiency in IBD treatment (9). 
Mitoma and coworkers (2005) have shown that infliximab causes cell cycle arrest, 
promotes apoptosis, and stimulates the production of IL-10, an anti-inflammatory 
cytokine, by reverse signal transduction in an immortalized human T-lymphocyte cells 
line (Jurkat cells) transfected with tmTNF-α (53). Further, studies have shown that in RA 
patients TNF-α inhibitors induce IL-10 expression in peripheral blood helper (CD4+) T 
lymphocytes, including those from patients suffering from RA that are the most 
pathogenic and produce IL-17 (54). This suggests that modulation of IL-10 expression in 
effector T cells may represent one of the mechanisms of action for TNF-α inhibitors. 
TNF-α inhibitors can induce cell apoptosis by direct activation of caspases or 
indirectly by blocking NF-κB activation and transcription of survival signals triggered by 
tmTNF-α binding to TNFR2 (4, 55, 56). Several studies have examined the in vivo effects 
of infliximab in patients with IBD and demonstrated that apoptosis induction in T 
lymphocytes and macrophages is important for the clinical efficacy of the drug (55, 57, 
58). 
Ten Hove and coworkers (2002) showed an increased number of apoptotic T cells 
in the colon tissue obtained by biopsy 24 h after infliximab infusion in patients with 
refractory CD. Apoptotic T cells were not found among the patients' peripheral blood 
cells (55). Another study examining the same drug in CD patients showed that the main 
target cells in the colonic lamina propria that undergo apoptosis are CD4+ T cells (57). 
Administration of infliximab also increases apoptosis of macrophages in the lamina 
propria of intestinal mucosa of IBD patients and consequently decreases their number, 
which was associated with recovery and healing of the mucosa (58). In vitro, infliximab 
was more potent in inducing apoptosis of CD8+ T lymphocytes than of CD4+ T 
lymphocytes isolated from the inflamed skin of patients with psoriasis (59). However, 
TNF-α inhibitors differ in their ability to induce apoptosis. Nesbitt and coworkers (2007) 
found that infliximab and adalimumab, contrary to certolizumab pegol, increase the 
number of apoptotic monocytes and peripheral blood lymphocytes in vitro (52). Also, 
etanercept shows a weaker proapoptotic effect compared with infliximab and 
adalimumab, and this might be one of the reasons for its ineffectiveness in the treatment 




induce mucosal T cell apoptosis in IBD indirectly, by targeting the tmTNF/TNFR2 
pathway. Namely, the development of granulomatous inflammation which is present in 
CD largely depends on the anti-apoptotic signal induced by ligation of monocytic tmTNF-
α to TNFR2 expressed by mucosal CD4+ T cells, and inhibition of this interaction by 
anti-TNF antibodies leads to lamina propria T cell apoptosis (56).  
Furthermore, TNF-α inhibitors with the Fc region can induce apoptosis by 
antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC) reactions (4).   
Antibody-dependent cellular cytotoxicity 
ADCC is a mechanism of the adaptive immune system in which antibody-tagged 
target cells are killed via a non-phagocytic mechanism (60). Therefore, upon antibody 
binding to its target cell, the Fc domain is recognized by the FcR on effector immune 
cells. The best- known mechanism utilized by ADCC reactions is the release of perforin 
and granzymes from NK cell granules, with subsequent apoptosis of the target cell (60). 
It was found that infliximab, adalimumab, golimumab, and etanercept induce 
apoptosis of Jurkat T lymphocytes transfected with tmTNF-α in the presence of human 
peripheral blood mononuclear cells (PBMNC) and NK cells (3). Also, infliximab and 
adalimumab were more potent than etanercept in the induction of apoptosis of different 
cells transfected with tmTNF-α (52, 61), even though all three TNF-α inhibitors have 
domains that interact with FcR on effector cells (3). Finally, as expected, certolizumab 
pegol did not induce an ADCC reaction in vitro (52), since it does not possess an Fc 
region (4). 
Complement-dependent cytotoxicity 
In the CDC, antibodies bound to target cells can activate the complement system, 
which results in cell death (4). The capability of TNF-α inhibitors to induce CDC was 
examined and proved in vitro on different cell lines transfected with tmTNF-α (38, 39, 
41, 52, 61). Infliximab, adalimumab, and golimumab have greater potential for CDC 
induction than etanercept (38, 39, 52, 61), probably due to different structural 
characteristics (38, 39, 52, 61). Namely, infliximab, adalimumab, and golimumab are full 
IgG1 mAbs which contain all three CH domains and successfully activate the 
complement system (3). Unlike them, etanercept has a CH2 domain of IgG1 mAb and 
binds C1, the first complement component, but does not have a CH1 domain, which 
serves as a platform for the binding of C3 complement component and is required for full 
activation of the complement system (3). As expected, certolizumab pegol did not show 
any CDC activity, since it does not have an Fc region (3).  
Despite the potential of TNF-α inhibitors to induce CDC of tmTNF-α-transfected 




an important mechanism of their action in the treatment of inflammatory diseases. 
Namely, in order to examine this effect in a system that would resemble the conditions of 
inflammatory diseases as closely as possible, they used in vitro activated normal human 
PBMNC as targets and showed that infliximab, adalimumab, and etanercept did not 
induce a CDC reaction (38).  
Anti-inflammatory effect of TNF-α inhibitors 
In addition to the aforementioned findings indicating anti-inflammatory effects of 
anti-TNF-α drugs, additional data proving this effect will be mentioned below. Thus, 
Butler and coworkers (1995) showed that the presence of anti-TNF-α antibody in 
rheumatoid synovial membrane cell cultures inhibited the production of proinflammatory 
cytokines (IL-1β, IL-8, IL-6). Shortly thereafter, reduced migration of radiolabeled 
granulocytes into the synovial membrane of inflamed joints in infliximab-treated RA 
patients was shown (62). Synovial membrane biopsies of these patients also showed a 
decreased number of T lymphocytes, B lymphocytes, and macrophages and diminished 
expression of IL-8 and monocyte chemoattractant protein-1 (MCP-1), regulating 
monocytes/macrophages migration and infiltration into tissues (62). 
The use of TNF blockers in the treatment of CD patients decreases the expression 
of proinflammatory cytokines (IFN-γ, TNF-α, IL-1β) and other mediators of 
inflammation, and suppresses chronic inflammation (2, 63, 64). This therapy 
downregulates the expression of CD40 (maturation/activation marker) on intestinal 
dendritic cells which is expressed at significantly higher levels on cells of this type from 
CD patients (65). In these patients, the concentration of CD40 ligand in plasma (soluble 
form) and its expression on peripheral blood T lymphocytes, as well as expression of 
CD40 and VCAM-1 adhesion molecules on blood vessel endothelial cells in intestinal 
mucosa were also diminished after treatment with TNF-α inhibitors (66). Additionally, 
therapy with TNF-α inhibitors in IBD patients prevents leukocytes from migrating to the 
site of inflammation by suppressing the expression of chemokines and chemokine 
receptors (67). It also inhibits intestinal fibroblasts to produce vascular endothelial growth 
factor, leading to reduced angiogenesis in the intestinal mucosa (68). It is supposed that 
all abovementioned effects are the results of the blockade of TNFR-mediated signal 
transduction (66, 68) or the induction of reverse signalling (64, 69). 
Effect on helper and regulatory T lymphocytes 
TNF-α blockade in mice with collagen-induced arthritis (an animal model of RA) 
ameliorates clinical symptoms of disease (70). The number of pathogenic CD4+ T cells 
that produce IFN-γ and IL-17 was increased in lymph nodes from these animals, but their 
migration to the inflamed joints was prevented (70). It was previously mentioned that 
TNF-α inhibitors induce the expression of IL-10 in peripheral blood IL-17-producing 




A study by Nguyen and coworkers (2016) examined the effect of adalimumab and 
etanercept on regulatory T cells (Treg) in RA patients and healthy controls. They found 
that monocytes of RA patients exhibit higher levels of tmTNF-α than those of healthy 
controls (71). Furthermore, binding of adalimumab, but not etanercept, to tmTNF-α on 
monocytes, increases the expression of this molecule on monocytes in patients with RA, 
contrary to cells derived from healthy subjects (71). Furthermore, adalimumab had a 
positive effect, which is a paradox, on the interaction of tmTNF-α on monocytes and 
TNFR2 on Treg, leading to the expansion of Treg (3). On the other hand, etanercept did 
not affect Treg expansion in patients with RA (71). Other TNF-α inhibitors (infliximab, 
golimumab, and certolizumab pegol) were not included/tested in this study (3, 71). 
Patients with UC and CD, in response to infliximab, adalimumab, and certolizumab 
pegol therapy, increase the frequency of Treg in peripheral blood (64, 72). This increase 
in Treg correlates with decreased apoptosis, so it is assumed that the prevention of Treg 
apoptosis is one of the mechanisms of action of TNF-α inhibitors (73). A study by Li and 
coworkers (2015) showed that IBD patients had a reduced number of Treg in circulation 
and that the increase in the number of these cells, preceding infliximab therapy correlated 
with good response to therapy. It has also been shown that a higher basal number of 
circulating Treg in patients before therapy, positively correlates with the ability to achieve 
remission after therapy (74). In this regard, it is suggested that Treg number could be a 
useful predictor of response to anti-TNF therapy and a parameter that could serve to 
monitor the effectiveness of this therapy (74). 
Induction of regulatory (alternatively activated) macrophages 
One of the major mechanisms of action of TNF-α inhibitors is the effect they exert 
on monocytes/macrophages by binding to FcR (44, 75). The significance of this 
mechanism, at least in the treatment of IBD, is indicated by the fact that anti-TNF-α IgG4 
mAb, marked as CDP571, did not achieve the desired effect in the treatment of CD (44). 
Namely, this antibody was designed as IgG4 in order to reduce its interaction with FcR, 
since the IgG4 subclass has a low affinity for binding to FcR (44). However, this change 
of subclass could be the main cause of its inefficiency in the treatment of CD (44). 
Vos and coworkers (2011) showed that in mixed leukocyte reaction mAbs 
(infliximab or adalimumab), but not etanercept and certolizumab pegol, inhibit T 
lymphocyte proliferation. Inhibition of lymphocyte proliferation did not occur in mixed 
leukocyte reaction when Fc blockers were added, further confirming the significance of 
the Fc region for the obtained findings (44). It is supposed that bridging of tmTNF-α on 
lymphocytes with FcR on monocytes/macrophages by anti-TNF-α antibodies induced the 
differentiation of monocytes into regulatory (mainly IL-10-producing) macrophages that 
inhibit lymphocyte proliferation (44). In line with these in vitro findings are data that in 




mucosa correlates with the induction of regulatory macrophages (75). However, these 
cells were not found in patients who did not respond to infliximab therapy (75). 
Interestingly, the effect of combined therapy (infliximab plus azathioprine) was more 
potent in this respect than the effect of infliximab as a monotherapy (75). 
Another factor that might be important for the induction of regulatory macrophages 
is the binding ability of complexes consisting of sTNF-α/tmTNF-α and anti-TNF-α drugs 
to FcR (3), where larger complexes have a greater binding ability (61). On the contrary, 
Wojtaland and coworkers (2012) have shown that binding of infliximab/TNF-α complex 
to FcR on PBMNC from patients with IBD leads to the classical activation of these cells 
and the production of proinflammatory mediators (MCP-1, IL-6 and IL-8). Adalimumab 
showed a similar effect, whereas certolizumab pegol, as well as F(ab´)2 fragments of 
infliximab, did not, suggesting the importance of the Fc portion for this effect (3). 
Significantly higher expression of mRNA for activating FcR which binds IgG antibodies 
(FcγRI) in the colon from patients who did not respond to infliximab therapy could, at 
least partly, explain its failure in CD therapy (45). Having in mind that 
monocytes/macrophages express different types of FcR, both activating and inhibitory, 
and that IgG1 can bind to any of them, it is obvious that signal transduction via these 
receptors is extremely complex (3). Thus, the outcome of ligand/anti-TNF-α antibody 
complex binding to FcγR (proinflammatory or antiinflammatory response) and clinical 
response to these drugs could depend on the expression level of each of the receptor types 
and the presence of their polymorphism(s) (3). 
Conclusion 
Biological drugs that inhibit TNF-α have been present in clinical practice for more 
than two decades for the treatment of various autoimmune and inflammatory diseases 
where an overproduction of TNF-α, a potent proinflammatory cytokine, has an important 
role in pathogenesis. To date, five TNF-α inhibitors have been approved: infliximab, 
adalimumab, golimumab (mAbs), certolizumab pegol (PEGylated Fab’), and etanercept 
(TNFR2: Fc-fusion protein).  
All TNF-α inhibitors are effective in the treatment of RA. However, in the treatment 
of IBD, infliximab, adalimumab, and golimumab have a beneficial effect, while 
etanercept has no effect.   
The mechanisms of action of TNF-α inhibitors are complex. The main mechanism 
of their action is to neutralise sTNF-α activity and prevent its binding to TNFR1 and 
TNFR2 and signalling via these receptors. However, it was shown that they exert its 
clinical effects by binding to tmTNF-α, and either block cell to cell contact and/or trigger 
reverse signalling. Besides, if anti-TNF-α agents have an Fc fragment, they mediate the 




Also, TNF-α inhibitors containing Fc fragment may stimulate FcR-expressing cells and 
have an effector function quite independent of their TNF-α neutralisation capacity.   
Having all the abovementioned in mind it seems that the therapeutic efficacy of 
inhibitors of TNF-α is a result of multiple mechanisms acting together and revealing these 
mechanisms will be helpful in the design of future therapeutics and the selection of 
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Faktor nekroze tumora (TNF)-α je citokin koji ima značajnu ulogu u patogenezi nekih 
autoimunskih/inflamatornih bolesti. Shodno tome, dizajnirani su biološki lekovi koji ciljano 
inhibiraju efekte koje on ostvaruje posredstvom svojih receptora. Do danas je odobreno pet lekova 
koji inhibiraju TNF-α: infliksimab, adalimumab, golimumab (monoklonska antitela), 
certolizumab pegol (pegilovani antigen-vezujući fragment imunoglobulina) i etanercept [TNF 
receptor 2-kristalizujući fragment (Fc) imunoglobulina fuzioni protein]. Takođe, brojni 
biosimilari ovih lekova su odobreni za primenu. Glavne indikacije za primenu anti-TNF-α lekova 
su: reumatoidni artritis, inflamatorne bolesti creva, psorijaza. Iako se TNF-α inhibitori više od 
dve decenije uspešno koriste u kliničkoj praksi, složeni mehanizmi njihovog delovanja još uvek 
nisu potpuno poznati. Naime, pokazano je da se ovi lekovi, osim vezivanja i neutralizacije 
solubilnog TNF-α, mogu vezati i za transmembransku formu ovog citokina i blokirati je i/ili 
pokrenuti prenos signala u ćeliju koja ispoljava ovaj molekul („reverzni prenos signala“). Takođe, 
ovi lekovi, ukoliko poseduju Fc fragment, mogu posredovati i u ubijanju ćelija koje ispoljavaju 
membransku formu TNF-α aktivacijom drugih ćelija imunskog sistema ili sistema komplementa 
ili modulisati funkciju ćelija koje ispoljavaju receptore za Fc fragmanet i ostvarivati efektorske 
funkcije nezavisno od njihove sposobnosti da blokiraju/neutrališu TNF-α. 
 
Ključne reči: TNF-α inhibitori; neutralizacija TNF-α; TNF receptori;  
  transmembranski TNF-α 
 
